+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Host defence (cationic) peptides: what is their future clinical potential?

Host defence (cationic) peptides: what is their future clinical potential?

Drugs 57(4): 469-473

Host defence, cationic antimicrobial peptides are now recognised as an important component, in most species, of the early innate and induced defences against invading microbes. They are small (12 to 35 amino acids), cationic due to the presence of an excess of arginine and lysine over acidic amino acids, and able to fold into a variety of different secondary structures. They have highly desirable properties, such as the ability to kill rapidly a broad spectrum of microorganisms including drug resistant bacteria and often fungi at around the minimal inhibitory concentration, a low level of resistance development in vitro, the ability to protect animals against both topical and systemic infections and the capability to neutralise endotoxin and demonstrated synergy with conventional antibiotics. In addition, given the 20 building blocks (amino acids) for these peptides. even a small peptide offers enormous diversity and potential for design of improved variants. For this reason such peptides have entered clinical trials, largely as agents for topical therapy of polymicrobial infections and are considered to have excellent potential for being a novel antibiotic class.

(PDF emailed within 1 workday: $29.90)

Accession: 046274762

Download citation: RISBibTeXText

PMID: 10235687

Related references

Cationic host defence peptides: potential as antiviral therapeutics. Biodrugs 27(5): 479-493, 2014

Multifunctional cationic host defence peptides and their clinical applications. Cellular and Molecular Life Sciences 68(13): 2161-2176, 2011

Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cellular and Molecular Life Sciences 64(7-8): 922-933, 2007

Anti-endotoxin properties of cationic host defence peptides and proteins. Journal of Endotoxin Research 11(4): 230-236, 2005

Bactericidal cationic peptides involved in bacterial antagonism and host defence. Microbiological Sciences 2(7): 212-217, 1985

Cationic host defence peptides: multifaceted role in immune modulation and inflammation. Journal of Innate Immunity 4(4): 361-370, 2012

Function and therapeutic potential of host defence peptides. Journal of Peptide Science 11(11): 677-687, 2005

Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerging Health Threats Journal 2: E1, 2009

Cationic antimicrobial peptides : issues for potential clinical use. Biodrugs 17(4): 233-240, 2003

Clinical potential of engineered cationic antimicrobial peptides against drug resistant biofilms. Expert Review of Anti-Infective Therapy 14(11): 989-991, 2016

Contribution of Host Defence Proteins and Peptides to Host-Microbiota Interactions in Chronic Inflammatory Lung Diseases. Vaccines 6(3), 2018

In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrobial Agents and ChemoTherapy 55(9): 4012-4018, 2012

Role of host-defence peptides in eye diseases. Cellular and Molecular Life Sciences 68(13): 2201-2213, 2011

Host defence peptides in human burns. Burns 34(1): 32-40, 2007

Antimicrobial peptides in innate intestinal host defence. Gut 47(1): 16-17, 2000